Manufacturing

Julie Vickers is a subject matter expert in Process Engineering at Jacobs.

Peter Cramer is a subject matter expert in Process Architecture at Jacobs.

Ranna Eardley-Patel is a sustainable manufacturing lead at CEPI.

Oliver Excell is an implementation expert at PA Consulting.

Articles

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine Manufacturing 

Suzanne Shelley is contibuting editor to 

The option of using prefilled syringes for vaccinations is not (yet) available for all types of vaccines. Stakeholders are working to expand that option while also pursuing other non-traditional routes of administration.

Vaccine Administration: The Growing Role of Prefilled Syringes

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center

Editor of Pharmaceutical Technology Europe

Technological advances are progressing pharmaceutical packaging to overcome the challenges of the future.

Getting Proactive with Pharma Packaging

The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.

Seqirus Announces Completion of $156 Million Expansion of Vaccine Manufacturing Facility

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

EIB Provides €15 million to IRBM

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

ReiThera and Exothera Collaborate on Manufacturing Vaccines for Low and Middle-income Countries

IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.

IAVI and Moderna Partner to Tackle Global Health Priorities Using mRNA for Vaccines and Antibodies

Catalent has acquired the Vaccine Manufacturing Innovation Centre in Harwell, Oxford to expand its biologics capabilities across the UK and Europe.

Manufacturing, Vaccines